{"doc_desc":{"title":"National cohort on congenital defects of the eye: natural history, genetic determinisms and improved ocular and extra-ocular outcome prediction for better patient management","idno":"FRESH-PEF73377-en","producers":[{"name":"Sonia GUEGUEN","affiliation":"SORBONNE UNIVERSITE"}]},"study_desc":{"title_statement":{"idno":"FRESH-PEF73377-en","IDno":{"metadata_no":[{"agency":"PEF","code":"73377"},{"agency":"FReSH","code":"FRESH-PEF73377"}]},"title":"National cohort on congenital defects of the eye: natural history, genetic determinisms and improved ocular and extra-ocular outcome prediction for better patient management","alternate_title":"RaDiCo-ACOEIL"},"study_authorization":{"agency":[]},"authoring_entity":[{"type":"investigator","name":"Nicolas;CHASSAING","PILabo":"French National Institute for Health and Medical Research (Inserm) \/ Inserm U 1056","affiliationName":"INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)","extlink":[{"title":"ORCID","uri":"0000-0003-0234-8820","role":"pi id"},{"title":"IdRef","uri":"094599289","role":"pi id"},{"title":"SIREN","uri":"180036048","role":"organisation id"},{"title":"RNSR","uri":"201119394M","role":"labo id"}],"email":"chassaing.n@chu-toulouse.fr","isContact":"Yes"},{"type":"investigator","name":"Patrick;CALVAS","PILabo":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (Inserm)","affiliationName":"INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)","extlink":[{"title":"ORCID","uri":"0000-0002-7293-3382","role":"pi id"},{"title":"IdRef","uri":"06925446X","role":"pi id"},{"title":"SIREN","uri":"180036048","role":"organisation id"},{"title":"","uri":"","role":"labo id"}],"email":"calvas.p@chu-toulouse","isContact":"Yes"}],"oth_id":[{"name":"Healthcare Networks for Rare Diseases (National Rare Diseases Healthcare Networks): SENSGENE and ANDDIRARE","type":"collaboration"}],"production_statement":{"prod_place":"Epidemiology France Portal (PEF)","producers":[{"name":"INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)","extlink":[{"title":"ROR","uri":"https:\/\/ror.org\/02vjkv261","role":"sponsor id"},{"title":"SIREN","uri":"180036048","role":"sponsor id"}],"role":"sponsor"}],"funding_agencies":[{"name":"AGENCE NATIONALE DE LA RECHERCHE (ANR)","extlink":[{"title":"ROR","uri":"https:\/\/ror.org\/00rbzpz17"},{"title":"SIREN","uri":"130002504"}]}]},"distribution_statement":{"contact":[{"name":"Nicolas;CHASSAING","email":"chassaing.n@chu-toulouse.fr","type":"contact","affiliationName":"INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)","contactPointLabo":"","extlink":[{"uri":"https:\/\/ror.org\/02vjkv261","role":"organisation id","title":"ROR"},{"uri":"180036048","role":"organisation id","title":"SIREN"}]},{"name":"Patrick;CALVAS","email":"calvas.p@chu-toulouse","type":"contact","affiliationName":"INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)","contactPointLabo":"","extlink":[{"uri":"https:\/\/ror.org\/02vjkv261","role":"organisation id","title":"ROR"},{"uri":"180036048","role":"organisation id","title":"SIREN"}]}]},"study_info":{"keywords":[{"keyword":"Ophthalmic diseases"},{"keyword":"Rare diseases"},{"keyword":"Quality of life"}],"topics":[{"topic":"Neurology","vocab":"health theme","extLink":[{"title":"ESV","uri":"http:\/\/data.europa.eu\/8mn\/euroscivoc\/c4793dfe-e80e-49dd-9fcc-a1a742de1b25"},{"title":"ESV","uri":"http:\/\/data.europa.eu\/8mn\/euroscivoc\/00a5c4f4-b7ee-41a4-bcdf-3a02e6be1660"},{"title":"MeSH","uri":"http:\/\/id.nlm.nih.gov\/mesh\/D009462"}]},{"topic":"Ophthalmology","vocab":"health theme","extLink":[{"title":"ESV","uri":"http:\/\/data.europa.eu\/8mn\/euroscivoc\/621ef1ce-2ebd-43d9-a6c7-ecd962d27269"},{"title":"MeSH","uri":"http:\/\/id.nlm.nih.gov\/mesh\/D009885"}]},{"topic":"Paediatrics","vocab":"health theme","extLink":[{"title":"ESV","uri":"http:\/\/data.europa.eu\/8mn\/euroscivoc\/bf8aaaac-ddee-41cd-bb8a-c5a63de3fcbd"},{"title":"MeSH","uri":"http:\/\/id.nlm.nih.gov\/mesh\/D010372"}]},{"topic":"Structural developmental anomalies of ocular globes","vocab":"cim-11","extLink":[{"uri":"http:\/\/id.who.int\/icd\/entity\/702067523","title":"CIM-11"}]},{"topic":"Socio-demographic and economic determinants","vocab":"health determinant"},{"topic":"Biological determinants: Genetic predisposition","vocab":"health determinant"},{"topic":"Healthcare system determinants: Use of care","vocab":"health determinant"},{"topic":"Biological determinants","vocab":"health determinant"},{"topic":"Healthcare system determinants","vocab":"health determinant"}],"purpose":"Main objective The principal objective of this study is to delineate the long term outcomes of the patients with ocular developmental defects, focusing on visual and neuro-developmental issues. Secondary objectives I) Identification of prognostic factors (such as ocular defects, unilateral or bilateral involvement, extra-ocular malformations) that would be associated with unfavourable visual and\/or neurologic outcome. These data will be essential for the formulation of recommendations to enhance diagnosis and patient management. II) Repercussions of the ocular developmental defects on patients and families quality of life. Exploratory objectives Searching for potential genotype\/phenotype correlations to unravel - the frequency of implication of each gene in these ocular developmental defects; - the phenotypic spectrum associated with mutations in these genes; - the identification of novel genes involved in these ocular developmental defects. Given genotyping will not be mandatory to participate to the cohort; this objective will involve only the patients who accepted it.","abstract":"","coll_dates":[{"start":"2016-01-01","end":"2037-01-01"}],"nation":[{"name":"France","abbreviation":"fr","extLink":{"vocab":"ISO","vocabURI":"fr"}}],"geog_coverage":"","analysis_unit":"Individuals","universe":"{\n    \"level_sex_clusion_I\": [\n        {\n            \"value\": \"Male\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D008297\"\n            }\n        },\n        {\n            \"value\": \"Female\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D005260\"\n            }\n        }\n    ],\n    \"level_age_clusion_I\": [\n        {\n            \"value\": \"Infant, Newborn (birth to 28 days)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D007231\"\n            }\n        },\n        {\n            \"value\": \"Infant (28 days to 2 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D007223\"\n            }\n        },\n        {\n            \"value\": \"Child, Preschool (2 to 5 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D002675\"\n            }\n        },\n        {\n            \"value\": \"Child (6 to 12 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D002648\"\n            }\n        },\n        {\n            \"value\": \"Young Adult (19 to 24 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D055815\"\n            }\n        },\n        {\n            \"value\": \"Adult (25 to 44 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D000328\"\n            }\n        },\n        {\n            \"value\": \"Middle Aged (45 to 64 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D008875\"\n            }\n        },\n        {\n            \"value\": \"Aged (65 to 79 years)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D000368\"\n            }\n        },\n        {\n            \"value\": \"Aged, 80 and over (80 years and more)\",\n            \"concept\": {\n                \"vocab\": \"MeSH\",\n                \"vocabURI\": \"http:\\\/\\\/id.nlm.nih.gov\\\/mesh\\\/D000369\"\n            }\n        }\n    ],\n    \"level_type_clusion_I\": \"People with disabilities\",\n    \"level_type_clusion_other\": \"\",\n    \"clusion_I\": \"Patients from 0 to 7 years old - Newborns and\\\/or children from birth to 7 years old, affected with the following ocular defects: \u2022 anophthalmia, \u2022 microphthalmia \u2022 aniridia \u2022 anterior segment dysgnesis whose parents will have properly evaluated risks (those related to the actual standard of care for these pathologies) and benefits (improvement of knowledge and standard of care) of the study, and will be given an informed consent to participate the protocol. - Patients affiliated to the \\\"R\u00e9gime National d\u2019Assurance Maladie\\\" - Inclusion of foreign patients will be possible through the French inclusion centers when they agreed to be charged for all medical fees. Patients over 8 years old - Children from 8 years old, affected with the following ocular defects : \u2022 anophthalmia, \u2022 microphthalmia \u2022 aniridia \u2022 anterior segment dysgenesis whose parents will have properly evaluated risks and benefits of the study, and will be given an informed consent form to participate to the protocol. - Patients affiliated to the \\\"R\u00e9gime National d\u2019Assurance Maladie\\\"  - Inclusion of foreign patients will be possible through the French inclusion centres when they agreed to be charged for all medical fees.  Adult Patients - Adults  affected with the following ocular defects : \u2022 anophthalmia, \u2022 microphthalmia \u2022 aniridia \u2022 anterior segment dysgenesis - Adult patients under guardianship whose guardians will have properly evaluated risks (those related to the actual standard of care for these pathologies) and benefits (improvement of knowledge and standard of care) of the study, and will be given an informed consent to participate the protocol. Indeed, intellectual disability may be associated with the ocular defects and we will need to include these patients in order to evaluate incidence of this event. - Adult patients able to properly evaluate risks (those related to the actual standard of care for these pathologies) and benefits (improvement of knowledge and standard of care) of the study and to give their informed consent to participate to the protocol. - Adult parents of an affected child participating to the study and willing to participate to the inheritance study (results of DNA analysis). - Patients affiliated to the \\\"R\u00e9gime National d\u2019Assurance Maladie\\\". - Inclusion of foreign patients will be possible through the French inclusion centres when they agreed to be charged for all medical fees. - Pregnant women can be included in the study (as examination proposed have no interference or adverse effect during pregnancies).  \",\n    \"clusion_E\": \" Patients with ocular developmental defects other than the ones listed above. - Patient or patients\u2019 parents\\\/tutor not able to approve or declining participation to the protocol. - French patients not affiliated to the \\\"R\u00e9gime National d\u2019Assurance Maladie\\\" or foreign patients not willing to pay charges of medical services.\"\n}","data_kind":"['Clinical data','Participant-reported health data','Biological data','Socio-demographic data']","quality_statement":{"standards":[{"name":"['HPO, ICD10, Snomed CT, Orpha Codes and ORDO, Drug dictionary (DCIs)']","committee":"","governance":""}],"other_quality_statement":"['Continuous data management; Data Management Plan and Data Validation Plan. Native controls and Query system']"}},"study_development":{"development_activity":[{"activity_type":"primary evaluation","activity_description":"Health event\/morbidity\r\nHealth event\/mortality\r\nQuality of life\/health perception\r\nOthers"}]},"method":{"data_collection":{"time_method":"","frequency":"","sampling_procedure":"['{\"concept\":{\"vocabURI\":\"Other\",\"vocab\":\"CESSDA\"},\"value\":\"Other\"}']","sample_frame":{"frame_unit":{"unit_type":"['Through organizations (health services or institutions, schools, businesses, etc.)']"}},"coll_mode":["{\"concept\":{\"vocabURI\":\"Transcription\",\"vocab\":\"CESSDA\"},\"value\":\"Converting or copying information into a structured record\"}"],"research_instrument":"Access on specific project only","sources":[],"target_sample_size":"[500-1000[ individuals","response_rate":"800"},"method_notes":"Observational Study","study_class":"Unknown","notes":[{"subject":"research type","values":["Observational Study"]},{"subject":"observational study method","values":["Morbidity registry"]}]},"data_access":{"dataset_availability":{"access_place":"","complete":"","status":"{\"value\":\"Restricted access\",\"extLink\":[{\"title\":\"COAR\",\"uri\":\"http:\/\/purl.org\/coar\/access_right\/c_16ec\"}]}"},"dataset_use":{"restrictions":"","conditions":"Access requests to RaDiCo -AC OEIL data (rough \/ structured), or to analytic reports will be examined by the scientific committee following submission of a Specific Research Project (SRP) synopsis, as defined in the Resource Access Charter. Must be sent to ac-oeil@radico.fr","conf_dec":[{"txt":""}],"spec_perm":[{"txt":"","required":""}],"contact":[{"name":""}],"deposit_req":"","cit_req":""},"notes":""}},"additional":{"IsImport":true,"versionLang":"en","originLang":"en","autoTranslation":false,"status":"imported","creationDate":"03-01-2017","lastUpdatedAuto":null,"lastUpdatedManual":"03-12-2024","isContributorPI":"No","contributorName":"Sonia GUEGUEN","contributorAffiliation":"SORBONNE UNIVERSITE","addTeamMember":"","obtainedAuthorization":{"otherAuthorizingAgency":[]},"relatedDocument":[],"regulatoryRequirements":{"conformityDeclaration":""},"fundingAgent":{"fundingAgentType":["Public (France)"],"otherFundingAgentType":[""]},"sponsor":{"sponsorType":["Public (France)"],"otherSponsorType":[""]},"governance":{"committee":"Yes"},"collaborations":{"networkConsortium":"Yes"},"theme":{"complementaryInformation":"","RareDiseases":"Yes"},"activeFollowUp":{"isActiveFollowUp":"Yes","followUpModeOther":""},"interventionalStudy":{"researchPurpose":[],"trialPhase":[],"interventionalStudyModel":"","isClinicalTrial":"","otherResearchPurpose":""},"isInclusionGroups":"","allocation":{"allocationMode":"","allocationUnit":""},"masking":{"maskingType":"","blindedMaskingDetails":[]},"arms":[],"intervention":[],"inclusionGroups":[],"collectionProcess":{"collectionModeDetails":"Electronic Case Report Form (eCRF) using REDCap EDC; Cloud-based platform, accessible via the web, secure by design. Certified Health Data Hosting resource (HADS).","collectionModeOther":""},"dataCollection":{"inclusionStrategyOther":"","samplingModeOther":"","recruitmentSourceOther":"","otherDocumentation":""},"dataCollectionIntegration":{"isDataIntegration":"No"},"geographicalCoverage":{"geoDetail":"All French territory via rare disease reference and competence centers"},"dataTypes":{"clinicalDataDetails":"clinical data, as well as biological, uniform molecular and comparative data of patients suffering from ocular congenital malformations. The retrieved data are dedicated to:- Implement the family history including the pregnancy and delivery follow-up; - The description of patient\u2019s phenotype (either ocular and extra-ocular); - The collection of paraclinic investigations data; - The description of visual and neurologic status;; - The evaluation of sociological state and quality of life","biologicalDataDetails":"For patients agreeing to have such analysis, molecular screening for diagnosis purposes will be performed by the genetic diagnosis laboratory led by the two principal investigators at the CHU (University Hospital) Toulouse. These analyses include the high-throughput sequencing of, to date, 25 genes known to be involved in these pathologies (ALDH1A3, B3GALTL, BCOR, C12ORF57, CYP1B1, FOXC1, FOXE3, MAB21L2, MFRP, OTX2, PAX2, PAX6, PITX2, PITX3, PRSS56, PXDN, RARB, RAX, RCN1, SIX6, SMOC1, SOX2, STRA6, TENM3, VSX2), and possibly more once new genes will be identified. These analyses are performed by Sanger, targeted sequencing (NGS).; Further molecular analysis for research purposes that may be required for identification of new or modulator genes, will be performed by the EA-4555 research laboratory (research laboratory of the two principal investigators). These analyses will be performed by whole exome and whole genome sequencing.","isDataInBiobank":"No","biobankContent":[],"biobankContentOther":"","dataTypeOther":""},"variableDictionnary":{"variableDictionnaryAvailable":"","variableDictionnaryLink":""},"dataQuality":{"otherDocumentation":""},"mockSample":{"mockSampleAvailable":"","mockSampleLocation":""},"thirdPartySource":{"otherSourceType":[]},"isHealthTheme":"Yes","fileDscr":{"fileTxt":{"fileCitation":{"titlStmt":{"IDno":[]}}}}},"schematype":"survey"}